{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-26-000256","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2026-08-03T20:09:43+00:00","discovered_at":"2026-08-03T20:11:00.324982+00:00","generated_at":"2026-08-03T20:11:32.839140+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vertex Q2 revenue $3.33B (+12% YoY); raises FY revenue guidance to $13.1-13.2B; announces $10B Crinetics acquisition","bullets":["Total revenue $3.33B, up 12% YoY; GAAP net income $1.1B, non-GAAP $1.2B.","Full-year 2026 revenue guidance raised to $13.1-13.2B from $12.95-13.1B.","CASGEVY revenue $76M (+151% YoY); JOURNAVX revenue $50M (quadrupled YoY).","Entered agreement to acquire Crinetics for $85/share, total equity value ~$10B; close expected Q3 2026.","Povetacicept PDUFA date Nov 30, 2026 for IgAN."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-26-000256","json":"https://secwatch.observer/filing/0000875320-26-000256.json","markdown":"https://secwatch.observer/filing/0000875320-26-000256.md","text":"https://secwatch.observer/filing/0000875320-26-000256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/0000875320-26-000256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/vrtx-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:11:32.839140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}